NCT05991583View on ClinicalTrials.gov

A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

July 3, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

December 30, 2025

Conditions

Advanced Malignant Tumors

Interventions

DRUG

IBB0979

IBB0979 should be subcutaneous injected，qw

Trial Locations (1)

200120

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

SUNHO（China）BioPharmaceutical CO., Ltd.

INDUSTRY